HLB "Camrelizumab Approved as Second-Line Liver Cancer Treatment in China... Global Phase 3 Trial with Lenvatinib Shows Positive Signs"
[Asia Economy Reporter Hyunseok Yoo] HL Biopharma announced on the 6th that Camrelizumab, being developed as a first-line treatment for liver cancer in combination with Lenvatinib and Camrelizumab (SHR-1210) from Hansoh Pharmaceutical, has received approval from the National Medical Products Administration (NMPA) of China for use as a monotherapy second-line treatment for liver cancer.
Camrelizumab is a PD-1 antibody developed by Hansoh Pharmaceutical, operating via the same mechanism as BMS's Opdivo and MSD's Keytruda. After being approved last May as a third-line treatment for Hodgkin lymphoma, this marks its second additional indication approval.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Sold Everything Fearing Bankruptcy, Then It Soared 3,900 Times: How a Stock Once Feared for Delisting Became an AI Powerhouse"
- "All Major Corporations Could Leave"... Business Community Fears Overseas Factory Relocation Due to Strike Risks
- Fiscal Pressure Mounts Amid Surging U.S. Treasury Yields...Exceeds Supplementary Budget Estimate by 0.04%p
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
An HL Biopharma official stated, "The approval of Camrelizumab as a liver cancer treatment in China yesterday is expected to be an important milestone for us, who are conducting a global Phase 3 clinical trial of the combination therapy of Lenvatinib and Camrelizumab as a first-line treatment for liver cancer," adding, "The clinical trial will gain further momentum."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
